首頁 › 子宮內膜癌 › 賓夕法尼亞州 › Philadelphia
Philadelphia, PA 的 子宮內膜癌 臨床試驗
28 項針對 子宮內膜癌 的研究正在 Philadelphia（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
招募中3 期
- Thomas Jefferson University Hospital, Philadelphia
- Jefferson Torresdale Hospital, Philadelphia
- Asplundh Cancer Pavilion, Willow Grove · 距離 13 英里
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
招募中2 期
- Pennsylvania Hospital, Philadelphia
- Thomas Jefferson University Hospital, Philadelphia
- Fox Chase Cancer Center, Philadelphia
- 還有 4 項
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
招募中1/2 期
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
招募中1 期
- NRG Oncology, Philadelphia
- University of Pennsylvania/Abramson Cancer Center, Philadelphia
- Thomas Jefferson University Hospital, Philadelphia
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
招募中1 期
- Sidney Kimmell Cancer Center - Jefferson Health, Philadelphia
Study of AVZO-021 in Patients With Advanced Solid Tumors
招募中1/2 期
- Avenzo Therapeutics Recruiting Site, Philadelphia
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
招募中2 期
- UPMC Hillman Cancer Center - Part of Frick Hospital, Mount Pleasant · 距離 8 英里
DESTINY-PANTUMOUR04
招募中觀察性研究
- Research Site, Philadelphia
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
招募中1 期
- Research Site, Philadelphia
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
招募中2 期
- Thomas Jefferson University, Philadelphia
- Lankenau Medical Center, Wynnewood · 距離 7 英里
- Asplundh Cancer Pavilion, Willow Grove · 距離 13 英里
- 還有 1 項
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
招募中1/2 期
- Perelman School of Medicine at the University of Pennsylvania, Philadelphia
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
招募中3 期
- Hospital of the University of Pennsylvania ( Site 5007), Philadelphia
PROton Therapy for Post Surgical Treatment of GYNecologic Cancer
招募中2 期
- University of Pennsylvania, Philadelphia
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
招募中觀察性研究
- University of Pennsylvania, Philadelphia
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
招募中3 期
- Research Site, Philadelphia
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
招募中1 期
- Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
招募中1/2 期
- Children's Hospital of Philadelphia, Philadelphia
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
招募中1 期
- Sidney Kimmel Comprehensive Center at Jefferson, Philadelphia
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
招募中1/2 期
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
招募中1 期
- SCRI - Sydney Kimmel Cancer Center - Jefferson Health, Philadelphia
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
招募中1 期
- Normunity Investigational Site, Philadelphia
- Normunity Investigational Site, Philadelphia
FOG-001 in Locally Advanced or Metastatic Solid Tumors
招募中1/2 期
- University of Pennsylvania, Perelman School of Medicine, Philadelphia
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
招募中1/2 期
- University of Pennsylvania / Abramson Cancer Center, Philadelphia
- Thomas Jefferson University, Sidney Kimmel Cancer Center, Clinical Research Organization, Philadelphia
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
招募中3 期
- Research Site, Philadelphia
- Research Site, Willow Grove · 距離 13 英里
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
招募中1 期
- Sidney Kimmel Cancer Center, Philadelphia
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
招募中1/2 期
- Thomas Jefferson University, Sidney Kimmel Comprehensive Cancer Center, Philadelphia
CYTALUX for Intraoperative Imaging of Patients With Endometrial Cancer
招募中早期第 1 期
- Abramson Cancer Center at Penn Medicine, Philadelphia
- University of Pennsylvania Gynecologic Oncology Department, Philadelphia
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
招募中觀察性研究
- Massive Bio SYNERGY-AI site, Philadelphia
其他城市的 子宮內膜癌 試驗
- Houston, TX68 項研究
- New York City, NY52 項研究
- Boston, MA50 項研究
- Arlington, VA39 項研究
- Nashville, TN38 項研究
- Los Angeles, CA34 項研究
- St. Louis, MO29 項研究
- San Antonio, TX27 項研究
- Columbus, OH25 項研究
- Chicago, IL25 項研究
- Oklahoma City, OK25 項研究
- Queens, NY25 項研究
Philadelphia 的其他研究
- 癌症（所有類型）59 項研究
- 乳癌56 項研究
- 非小細胞肺癌51 項研究
- 轉移性癌症46 項研究
- 前列腺癌44 項研究
- 大腸直腸癌44 項研究
- 卵巢癌44 項研究
- 肺癌36 項研究
- 急性髓系白血病34 項研究
- 心臟衰竭31 項研究
- 憂鬱症26 項研究
- 胰臟癌26 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。